25 XP   0   0   10

Nurix Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Nurix Therapeutics Inc together

PenkeI guess you are interested in Nurix Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Nurix Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Nurix Therapeutics Inc

I send you an email if I find something interesting about Nurix Therapeutics Inc.

Quick analysis of Nurix Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Nurix Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.67
Expected worth in 1 year
$1.70
How sure are you?
26.3%

+ What do you gain per year?

Total Gains per Share
$-1.96
Return On Investment
-13.4%

For what price can you sell your share?

Current Price per Share
$14.70
Expected price per share
$11.58 - $16.81
How sure are you?
50%

1. Valuation of Nurix Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$14.70

Intrinsic Value Per Share

$19.16 - $24.11

Total Value Per Share

$22.83 - $27.78

2. Growth of Nurix Therapeutics Inc (5 min.)




Is Nurix Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$200.4m$304.7m-$62.6m-25.9%

How much money is Nurix Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$34m-$43.4m$9.4m27.7%
Net Profit Margin-206.7%-465.8%--

How much money comes from the company's main activities?

3. Financial Health of Nurix Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#259 / 1031

Most Revenue
#224 / 1031

Most Profit
#859 / 1031

Most Efficient
#666 / 1031

What can you expect buying and holding a share of Nurix Therapeutics Inc? (5 min.)

Welcome investor! Nurix Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Nurix Therapeutics Inc.

What can you expect buying and holding a share of Nurix Therapeutics Inc?

First you should know what it really means to hold a share of Nurix Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Nurix Therapeutics Inc is $14.70. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nurix Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nurix Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.67. Based on the TTM, the Book Value Change Per Share is $-0.49 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.34 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nurix Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.77-5.2%-0.70-4.8%-0.89-6.1%-0.53-3.6%-0.53-3.6%
Usd Book Value Change Per Share-0.63-4.3%-0.49-3.3%-0.34-2.3%0.191.3%0.191.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.63-4.3%-0.49-3.3%-0.34-2.3%0.191.3%0.191.3%
Usd Price Per Share6.22-8.57-13.60-14.69-14.69-
Price to Earnings Ratio-2.03--3.08--3.83--6.48--6.48-
Price-to-Total Gains Ratio-9.85--19.99--8.31--29.63--29.63-
Price to Book Ratio1.70-1.91-2.24-2.41-2.41-
Price-to-Total Gains Ratio-9.85--19.99--8.31--29.63--29.63-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share14.7
Number of shares68
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.490.19
Usd Total Gains Per Share-0.490.19
Gains per Quarter (68 shares)-33.3613.13
Gains per Year (68 shares)-133.4552.50
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-133-14305343
20-267-276010596
30-400-4090158149
40-534-5420210202
50-667-6750263255
60-801-8080315308
70-934-9410368361
80-1068-10740420414
90-1201-12070473467
100-1335-13400525520

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.018.00.05.3%1.018.00.05.3%1.018.00.05.3%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%5.012.02.026.3%5.012.02.026.3%5.012.02.026.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.019.00.0%0.00.019.00.0%0.00.019.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%5.012.02.026.3%5.012.02.026.3%5.012.02.026.3%

Fundamentals of Nurix Therapeutics Inc

About Nurix Therapeutics Inc

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Fundamental data was last updated by Penke on 2024-03-21 01:28:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Nurix Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nurix Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nurix Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -276.8% means that $-2.77 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nurix Therapeutics Inc:

  • The MRQ is -276.8%. The company is making a huge loss. -2
  • The TTM is -206.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-276.8%TTM-206.7%-70.1%
TTM-206.7%YOY-465.8%+259.2%
TTM-206.7%5Y-322.0%+115.3%
5Y-322.0%10Y-322.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-276.8%-159.2%-117.6%
TTM-206.7%-202.3%-4.4%
YOY-465.8%-263.0%-202.8%
5Y-322.0%-452.4%+130.4%
10Y-322.0%-589.0%+267.0%
1.1.2. Return on Assets

Shows how efficient Nurix Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nurix Therapeutics Inc to the Biotechnology industry mean.
  • -11.5% Return on Assets means that Nurix Therapeutics Inc generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nurix Therapeutics Inc:

  • The MRQ is -11.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.5%TTM-9.8%-1.7%
TTM-9.8%YOY-10.2%+0.4%
TTM-9.8%5Y-8.2%-1.6%
5Y-8.2%10Y-8.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.5%-12.5%+1.0%
TTM-9.8%-12.2%+2.4%
YOY-10.2%-11.2%+1.0%
5Y-8.2%-13.3%+5.1%
10Y-8.2%-14.6%+6.4%
1.1.3. Return on Equity

Shows how efficient Nurix Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nurix Therapeutics Inc to the Biotechnology industry mean.
  • -20.9% Return on Equity means Nurix Therapeutics Inc generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nurix Therapeutics Inc:

  • The MRQ is -20.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -14.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.9%TTM-14.5%-6.4%
TTM-14.5%YOY-14.4%-0.1%
TTM-14.5%5Y-8.2%-6.3%
5Y-8.2%10Y-8.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.9%-16.0%-4.9%
TTM-14.5%-15.8%+1.3%
YOY-14.4%-13.9%-0.5%
5Y-8.2%-18.2%+10.0%
10Y-8.2%-19.1%+10.9%

1.2. Operating Efficiency of Nurix Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nurix Therapeutics Inc is operating .

  • Measures how much profit Nurix Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nurix Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -299.1% means the company generated $-2.99  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nurix Therapeutics Inc:

  • The MRQ is -299.1%. The company is operating very inefficient. -2
  • The TTM is -241.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-299.1%TTM-241.7%-57.4%
TTM-241.7%YOY-508.8%+267.2%
TTM-241.7%5Y-369.6%+128.0%
5Y-369.6%10Y-369.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-299.1%-299.5%+0.4%
TTM-241.7%-208.5%-33.2%
YOY-508.8%-280.2%-228.6%
5Y-369.6%-459.9%+90.3%
10Y-369.6%-596.9%+227.3%
1.2.2. Operating Ratio

Measures how efficient Nurix Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.99 means that the operating costs are $3.99 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Nurix Therapeutics Inc:

  • The MRQ is 3.991. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.490. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.991TTM3.490+0.501
TTM3.490YOY6.166-2.677
TTM3.4905Y4.630-1.140
5Y4.63010Y4.6300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9912.817+1.174
TTM3.4903.181+0.309
YOY6.1663.609+2.557
5Y4.6305.554-0.924
10Y4.6307.396-2.766

1.3. Liquidity of Nurix Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nurix Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.40 means the company has $3.40 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Nurix Therapeutics Inc:

  • The MRQ is 3.398. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.053. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.398TTM4.053-0.655
TTM4.053YOY4.558-0.505
TTM4.0535Y4.602-0.549
5Y4.60210Y4.6020.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3983.987-0.589
TTM4.0534.440-0.387
YOY4.5585.569-1.011
5Y4.6026.158-1.556
10Y4.6026.492-1.890
1.3.2. Quick Ratio

Measures if Nurix Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nurix Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 6.00 means the company can pay off $6.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nurix Therapeutics Inc:

  • The MRQ is 6.003. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 7.198. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.003TTM7.198-1.195
TTM7.198YOY7.964-0.766
TTM7.1985Y7.047+0.151
5Y7.04710Y7.0470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0033.653+2.350
TTM7.1984.158+3.040
YOY7.9645.515+2.449
5Y7.0476.012+1.035
10Y7.0476.206+0.841

1.4. Solvency of Nurix Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nurix Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nurix Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.45 means that Nurix Therapeutics Inc assets are financed with 45.0% credit (debt) and the remaining percentage (100% - 45.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nurix Therapeutics Inc:

  • The MRQ is 0.450. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.302. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.450TTM0.302+0.148
TTM0.302YOY0.288+0.015
TTM0.3025Y0.421-0.119
5Y0.42110Y0.4210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4500.336+0.114
TTM0.3020.330-0.028
YOY0.2880.267+0.021
5Y0.4210.367+0.054
10Y0.4210.378+0.043
1.4.2. Debt to Equity Ratio

Measures if Nurix Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nurix Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 81.8% means that company has $0.82 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nurix Therapeutics Inc:

  • The MRQ is 0.818. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.459. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.818TTM0.459+0.359
TTM0.459YOY0.406+0.053
TTM0.4595Y0.349+0.110
5Y0.34910Y0.3490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8180.376+0.442
TTM0.4590.398+0.061
YOY0.4060.334+0.072
5Y0.3490.431-0.082
10Y0.3490.476-0.127

2. Market Valuation of Nurix Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nurix Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Nurix Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.03 means the investor is paying $-2.03 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nurix Therapeutics Inc:

  • The EOD is -4.789. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.026. Based on the earnings, the company is expensive. -2
  • The TTM is -3.077. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.789MRQ-2.026-2.762
MRQ-2.026TTM-3.077+1.051
TTM-3.077YOY-3.829+0.752
TTM-3.0775Y-6.478+3.401
5Y-6.47810Y-6.4780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.789-2.697-2.092
MRQ-2.026-2.422+0.396
TTM-3.077-2.709-0.368
YOY-3.829-4.116+0.287
5Y-6.478-6.257-0.221
10Y-6.478-6.478+0.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nurix Therapeutics Inc:

  • The EOD is 10.484. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 4.436. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -1.937. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD10.484MRQ4.436+6.048
MRQ4.436TTM-1.937+6.373
TTM-1.937YOY-3.972+2.035
TTM-1.9375Y-3.044+1.107
5Y-3.04410Y-3.0440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.484-3.344+13.828
MRQ4.436-2.939+7.375
TTM-1.937-3.486+1.549
YOY-3.972-5.592+1.620
5Y-3.044-8.464+5.420
10Y-3.044-8.872+5.828
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nurix Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.70 means the investor is paying $1.70 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Nurix Therapeutics Inc:

  • The EOD is 4.008. Based on the equity, the company is fair priced.
  • The MRQ is 1.696. Based on the equity, the company is underpriced. +1
  • The TTM is 1.911. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD4.008MRQ1.696+2.312
MRQ1.696TTM1.911-0.215
TTM1.911YOY2.243-0.331
TTM1.9115Y2.405-0.494
5Y2.40510Y2.4050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0082.198+1.810
MRQ1.6962.042-0.346
TTM1.9112.121-0.210
YOY2.2432.907-0.664
5Y2.4053.682-1.277
10Y2.4054.114-1.709
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Nurix Therapeutics Inc.

3.1. Institutions holding Nurix Therapeutics Inc

Institutions are holding 98.768% of the shares of Nurix Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc9.49750.001246437361251822.7704
2023-12-31Baker Bros Advisors LP7.93990.4559388212500
2023-12-31ARK Investment Management LLC6.53450.1952319499960195223.2141
2023-12-31Morgan Stanley - Brokerage Accounts6.41190.0029313503728816241137.1256
2023-12-31Deep Track Capital, LP6.13131.0332299783000
2023-09-30Redmile Group, LLC5.82651.06542848827-8482-0.2969
2023-12-31Wasatch Advisors Inc.5.62390.15632749745-814871-22.86
2023-12-31Vanguard Group Inc5.31370.00062598097-116748-4.3004
2023-12-31T. Rowe Price Associates, Inc.4.8880.00332389966119880.5041
2023-12-31Bain Capital Life Sciences Investors, LLC3.72821.8032182288300
2023-12-31Geode Capital Management, LLC2.20990.00121080523352383.3711
2023-12-31Dimensional Fund Advisors, Inc.2.04530.0031000044420014.384
2023-12-31State Street Corporation1.88430.0005921322-852746-48.0673
2023-12-31Candriam Luxembourg S.C.A.1.87780.0654918110-50000-5.1647
2023-12-31Pictet Asset Manangement SA1.58220.0088773588-124221-13.836
2023-12-31TCG Crossover Management, LLC1.46780.82147176547176540
2023-12-31Affinity Asset Advisors, LLC1.41141.3008690112440112176.0448
2023-12-31Charles Schwab Investment Management Inc1.27270.0016622297537219.4483
2023-12-31Goldman Sachs Group Inc1.15310.000556380020027455.0921
2023-12-31Nuveen Asset Management, LLC1.09190.0018533865-129395-19.5089
Total 77.89186.922238084560+3013283+7.9%

3.2. Funds holding Nurix Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31ARK Genomic Revolution6.47381.4709316532959497623.1476
2024-02-29ARK Genomic Revolution ETF5.66261.82862768694139980.5082
2024-02-29Vanguard Total Stock Mkt Idx Inv2.92340.0011142934900
2023-12-31US Small-Cap Growth II Equity Comp2.70460.0551322383-4227-0.3186
2023-12-31T. Rowe Price New Horizons2.70460.05521322383-4227-0.3186
2024-02-29iShares Russell 2000 ETF2.38670.02311166946-191-0.0164
2023-12-31Wasatch Ultra Growth1.97490.83199656109830711.3348
2023-12-31Wasatch Small Cap Value1.43760.507870291015916829.2727
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.38440.0082676886-785-0.1158
2023-09-30UBS: US Equity Small Cap Growth1.2050.215658917600
2024-02-29Belfius Equities Cure C Cap1.15170.368256309600
2023-12-31Candriam Global Equities Oncology1.15170.313563096-50000-8.1553
2023-10-31Pictet-Biotech P USD1.02690.2196502074-9211-1.8015
2024-01-31TIAA-CREF Quant Small-Cap Equity Instl1.02590.13235016108360019.9995
2023-12-31Xtrackers S&P Global Infra Swap ETF 1C0.98932.267848368800
2023-12-31Fidelity Small Cap Index0.96990.019347421855911.1931
2024-02-01iShares Russell 2000 Value ETF0.92380.03124517075720.1268
2024-01-31Candriam Eqs L Biotech C USD Cap0.7260.170735499200
2023-12-31Wasatch Micro Cap0.72090.5783524827567327.3376
2023-10-31Pictet-Global Megatrend Sel I USD0.7070.01823457035550.1608
Total 38.25079.115718702332+963799+5.2%

3.3. Insider Transactions

Insiders are holding 2.664% of the shares of Nurix Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-16Houte Hans VanSELL681210.02
2024-01-30Gwenn HansenSELL23347.99
2024-01-30Houte Hans VanSELL16717.99
2023-12-19Houte Hans VanSELL1090610
2023-10-31Christine RingSELL12325.2
2023-10-31Houte Hans VanSELL10805.2
2023-07-31Christine RingSELL14209.65
2023-07-31Gwenn HansenSELL18849.65
2023-07-31Houte Hans VanSELL12459.65
2023-05-01Christine RingSELL6829.88
2023-05-01Gwenn HansenSELL11369.88
2023-05-01Houte Hans VanSELL7219.88
2023-05-01Stefani WolffSELL3429.88

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Nurix Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.632-0.491-22%-0.343-46%0.193-427%0.193-427%
Book Value Per Share--3.6674.457-18%6.019-39%4.370-16%4.370-16%
Current Ratio--3.3984.053-16%4.558-25%4.602-26%4.602-26%
Debt To Asset Ratio--0.4500.302+49%0.288+56%0.421+7%0.421+7%
Debt To Equity Ratio--0.8180.459+78%0.406+102%0.349+134%0.349+134%
Dividend Per Share----0%-0%-0%-0%
Eps---0.767-0.703-8%-0.891+16%-0.528-31%-0.528-31%
Free Cash Flow Per Share--0.351-0.438+225%-0.850+343%-0.360+203%-0.360+203%
Free Cash Flow To Equity Per Share--0.441-0.400+191%-0.274+162%0.300+47%0.300+47%
Gross Profit Margin--1.0431.011+3%1.000+4%1.002+4%1.002+4%
Intrinsic Value_10Y_max--24.110--------
Intrinsic Value_10Y_min--19.159--------
Intrinsic Value_1Y_max---1.646--------
Intrinsic Value_1Y_min---1.619--------
Intrinsic Value_3Y_max---1.850--------
Intrinsic Value_3Y_min---1.829--------
Intrinsic Value_5Y_max--1.678--------
Intrinsic Value_5Y_min--1.291--------
Market Cap718743270.000+53%340049527.240465239912.120-27%688122185.543-51%733143694.982-54%733143694.982-54%
Net Profit Margin---2.768-2.067-25%-4.658+68%-3.220+16%-3.220+16%
Operating Margin---2.991-2.417-19%-5.088+70%-3.696+24%-3.696+24%
Operating Ratio--3.9913.490+14%6.166-35%4.630-14%4.630-14%
Pb Ratio4.008+58%1.6961.911-11%2.243-24%2.405-29%2.405-29%
Pe Ratio-4.789-136%-2.026-3.077+52%-3.829+89%-6.478+220%-6.478+220%
Price Per Share14.700+58%6.2208.568-27%13.595-54%14.694-58%14.694-58%
Price To Free Cash Flow Ratio10.484+58%4.436-1.937+144%-3.972+190%-3.044+169%-3.044+169%
Price To Total Gains Ratio-23.277-136%-9.849-19.986+103%-8.310-16%-29.626+201%-29.626+201%
Quick Ratio--6.0037.198-17%7.964-25%7.047-15%7.047-15%
Return On Assets---0.115-0.098-15%-0.102-11%-0.082-29%-0.082-29%
Return On Equity---0.209-0.145-31%-0.144-31%-0.082-61%-0.082-61%
Total Gains Per Share---0.632-0.491-22%-0.343-46%0.193-427%0.193-427%
Usd Book Value--200493000.000242070750.000-17%304724250.000-34%220955842.105-9%220955842.105-9%
Usd Book Value Change Per Share---0.632-0.491-22%-0.343-46%0.193-427%0.193-427%
Usd Book Value Per Share--3.6674.457-18%6.019-39%4.370-16%4.370-16%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.767-0.703-8%-0.891+16%-0.528-31%-0.528-31%
Usd Free Cash Flow--19164000.000-23676500.000+224%-43012750.000+324%-18372631.579+196%-18372631.579+196%
Usd Free Cash Flow Per Share--0.351-0.438+225%-0.850+343%-0.360+203%-0.360+203%
Usd Free Cash Flow To Equity Per Share--0.441-0.400+191%-0.274+162%0.300+47%0.300+47%
Usd Market Cap718743270.000+53%340049527.240465239912.120-27%688122185.543-51%733143694.982-54%733143694.982-54%
Usd Price Per Share14.700+58%6.2208.568-27%13.595-54%14.694-58%14.694-58%
Usd Profit---41956000.000-34015250.000-19%-43454000.000+4%-25733894.737-39%-25733894.737-39%
Usd Revenue--15159000.00019246750.000-21%9656750.000+57%9729473.684+56%9729473.684+56%
Usd Total Gains Per Share---0.632-0.491-22%-0.343-46%0.193-427%0.193-427%
 EOD+4 -4MRQTTM+9 -25YOY+15 -195Y+13 -2110Y+13 -21

4.2. Fundamental Score

Let's check the fundamental score of Nurix Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.789
Price to Book Ratio (EOD)Between0-14.008
Net Profit Margin (MRQ)Greater than0-2.768
Operating Margin (MRQ)Greater than0-2.991
Quick Ratio (MRQ)Greater than16.003
Current Ratio (MRQ)Greater than13.398
Debt to Asset Ratio (MRQ)Less than10.450
Debt to Equity Ratio (MRQ)Less than10.818
Return on Equity (MRQ)Greater than0.15-0.209
Return on Assets (MRQ)Greater than0.05-0.115
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Nurix Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5064.098
Ma 20Greater thanMa 5013.829
Ma 50Greater thanMa 10011.021
Ma 100Greater thanMa 2009.489
OpenGreater thanClose14.540
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-11-30. Currency in USD. All numbers in thousands.

Summary
Total Assets364,539
Total Liabilities164,046
Total Stockholder Equity200,493
 As reported
Total Liabilities 164,046
Total Stockholder Equity+ 200,493
Total Assets = 364,539

Assets

Total Assets364,539
Total Current Assets295,503
Long-term Assets69,036
Total Current Assets
Cash And Cash Equivalents 54,627
Short-term Investments 233,281
Net Receivables 800
Other Current Assets 6,795
Total Current Assets  (as reported)295,503
Total Current Assets  (calculated)295,503
+/-0
Long-term Assets
Property Plant Equipment 47,950
Long Term Investments 7,421
Long-term Assets Other 3,823
Long-term Assets  (as reported)69,036
Long-term Assets  (calculated)59,194
+/- 9,842

Liabilities & Shareholders' Equity

Total Current Liabilities86,958
Long-term Liabilities77,088
Total Stockholder Equity200,493
Total Current Liabilities
Short-term Debt 7,489
Accounts payable 6,401
Other Current Liabilities 24,970
Total Current Liabilities  (as reported)86,958
Total Current Liabilities  (calculated)38,860
+/- 48,098
Long-term Liabilities
Capital Lease Obligations 30,614
Long-term Liabilities  (as reported)77,088
Long-term Liabilities  (calculated)30,614
+/- 46,474
Total Stockholder Equity
Common Stock49
Retained Earnings -545,200
Accumulated Other Comprehensive Income -655
Other Stockholders Equity 746,299
Total Stockholder Equity (as reported)200,493
Total Stockholder Equity (calculated)200,493
+/-0
Other
Capital Stock49
Cash and Short Term Investments 287,908
Common Stock Shares Outstanding 54,670
Current Deferred Revenue48,098
Liabilities and Stockholders Equity 364,539
Net Debt -24,013
Net Invested Capital 200,493
Net Working Capital 208,545
Property Plant and Equipment Gross 74,199
Short Long Term Debt Total 30,614



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-11-302023-08-312023-05-312023-02-282022-11-302022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-08-312019-02-28
> Total Assets 
0
0
44,048
88,789
213,277
411,874
396,343
396,660
517,981
493,074
476,771
437,720
394,310
459,338
416,759
370,154
350,624
308,195
364,539
364,539308,195350,624370,154416,759459,338394,310437,720476,771493,074517,981396,660396,343411,874213,27788,78944,04800
   > Total Current Assets 
0
0
39,354
76,660
196,804
364,089
298,434
310,768
396,281
358,445
311,118
280,484
306,789
354,871
318,449
288,329
290,014
267,949
295,503
295,503267,949290,014288,329318,449354,871306,789280,484311,118358,445396,281310,768298,434364,089196,80476,66039,35400
       Cash And Cash Equivalents 
0
0
34,816
56,240
159,329
265,527
119,356
126,381
188,207
147,440
80,506
78,780
41,533
47,556
64,474
33,571
58,958
42,304
54,627
54,62742,30458,95833,57164,47447,55641,53378,78080,506147,440188,207126,381119,356265,527159,32956,24034,81600
       Short-term Investments 
0
0
2,904
0
14,174
88,716
161,792
176,692
197,814
196,458
215,214
183,198
255,746
296,922
244,667
243,575
222,219
216,548
233,281
233,281216,548222,219243,575244,667296,922255,746183,198215,214196,458197,814176,692161,79288,71614,17402,90400
       Net Receivables 
0
0
0
0
19,590
3,856
11,346
3,981
5,679
5,204
6,204
8,204
700
1,100
1,100
1,200
1,000
2,000
800
8002,0001,0001,2001,1001,1007008,2046,2045,2045,6793,98111,3463,85619,5900000
       Other Current Assets 
0
0
1,634
170
3,711
5,990
5,940
3,714
4,581
9,343
9,194
10,302
9,510
10,393
9,308
11,183
8,837
7,097
6,795
6,7957,0978,83711,1839,30810,3939,51010,3029,1949,3434,5813,7145,9405,9903,7111701,63400
   > Long-term Assets 
0
0
4,694
0
16,473
47,785
97,909
85,892
121,700
134,629
165,653
157,236
87,521
104,467
98,310
81,825
60,610
40,246
69,036
69,03640,24660,61081,82598,310104,46787,521157,236165,653134,629121,70085,89297,90947,78516,47304,69400
       Property Plant Equipment 
0
0
3,871
3,975
5,789
6,532
6,672
6,960
8,345
9,569
25,345
29,394
30,925
30,349
29,508
28,634
28,436
25,608
47,950
47,95025,60828,43628,63429,50830,34930,92529,39425,3459,5698,3456,9606,6726,5325,7893,9753,87100
       Long Term Investments 
0
0
506
0
9,110
40,898
90,890
77,191
110,440
121,480
137,189
123,685
51,538
69,125
63,879
48,449
27,463
9,882
7,421
7,4219,88227,46348,44963,87969,12551,538123,685137,189121,480110,44077,19190,89040,8989,110050600
       Other Assets 
0
0
0
570
1,574
355
91,237
1,741
2,915
3,580
3,119
4,157
5,058
4,993
4,923
0
4,711
4,756
0
04,7564,71104,9234,9935,0584,1573,1193,5802,9151,74191,2373551,574570000
> Total Liabilities 
0
0
101,762
110,396
106,694
104,254
106,074
126,527
119,803
117,857
134,469
131,803
127,571
116,793
113,063
96,102
90,703
74,378
164,046
164,04674,37890,70396,102113,063116,793127,571131,803134,469117,857119,803126,527106,074104,254106,694110,396101,76200
   > Total Current Liabilities 
0
0
16,137
30,033
34,436
41,012
44,539
47,972
46,844
50,680
66,258
66,049
72,665
67,500
70,655
64,878
72,262
61,493
86,958
86,95861,49372,26264,87870,65567,50072,66566,04966,25850,68046,84447,97244,53941,01234,43630,03316,13700
       Short-term Debt 
0
0
4,618
0
3,927
6,144
7,628
10,137
7,077
10,941
3,847
5,430
5,470
5,496
5,530
5,556
5,583
5,362
7,489
7,4895,3625,5835,5565,5305,4965,4705,4303,84710,9417,07710,1377,6286,1443,92704,61800
       Accounts payable 
0
0
1,598
2,127
4,903
3,611
3,412
4,388
5,405
3,861
6,650
6,014
6,142
6,053
5,064
5,629
4,525
2,187
6,401
6,4012,1874,5255,6295,0646,0536,1426,0146,6503,8615,4054,3883,4123,6114,9032,1271,59800
       Other Current Liabilities 
0
0
309
21,639
234
958
700
696
601
628
14,549
11,419
19,734
19,609
22,428
15,388
18,091
21,907
24,970
24,97021,90718,09115,38822,42819,60919,73411,41914,54962860169670095823421,63930900
   > Long-term Liabilities 
0
0
85,625
0
72,258
63,242
61,535
78,555
72,959
67,177
68,211
65,754
54,906
49,293
42,408
31,224
18,441
12,885
77,088
77,08812,88518,44131,22442,40849,29354,90665,75468,21167,17772,95978,55561,53563,24272,258085,62500
       Other Liabilities 
0
0
0
80,363
72,258
63,242
61,535
78,555
72,959
67,177
59,022
55,428
45,863
41,548
35,974
0
14,683
10,243
0
010,24314,683035,97441,54845,86355,42859,02267,17772,95978,55561,53563,24272,25880,363000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
500
0
0
0
500
0
0
0
0
00005000005000000000000
> Total Stockholder Equity
0
0
-57,714
-21,607
106,583
307,620
290,269
270,133
398,178
375,217
342,302
305,917
266,739
342,545
303,696
274,052
259,921
233,817
200,493
200,493233,817259,921274,052303,696342,545266,739305,917342,302375,217398,178270,133290,269307,620106,583-21,607-57,71400
   Common Stock
0
0
4
11
26
39
39
39
44
45
45
45
45
47
47
47
48
49
49
49494847474745454545443939392611400
   Retained Earnings Total Equity0000-401,252000-220,892-183,190-154,355-127,973-103,698000000
   Accumulated Other Comprehensive Income 
0
0
-2
0
139
138
87
49
30
-59
-608
-2,066
-3,085
-3,742
-4,319
-3,247
-1,903
-1,228
-655
-655-1,228-1,903-3,247-4,319-3,742-3,085-2,066-608-593049871381390-200
   Capital Surplus 
0
0
0
2,977
3,591
0
393,841
398,018
552,459
558,421
563,757
0
0
0
709,220
0
0
0
0
0000709,220000563,757558,421552,459398,018393,84103,5912,977000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
13,741
57
171,685
-20,647
393,841
398,018
552,459
558,421
563,757
571,363
578,605
700,775
709,220
719,237
728,038
738,240
746,299
746,299738,240728,038719,237709,220700,775578,605571,363563,757558,421552,459398,018393,841-20,647171,6855713,74100



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-11-30)

Gross Profit (+$)
totalRevenue76,987
Cost of Revenue-13,654
Gross Profit63,33363,333
 
Operating Income (+$)
Gross Profit63,333
Operating Expense-218,396
Operating Income-155,063-155,063
 
Operating Expense (+$)
Research Development181,615
Selling General Administrative42,902
Selling And Marketing Expenses6,121
Operating Expense218,396230,638
 
Net Interest Income (+$)
Interest Income11,115
Interest Expense-0
Other Finance Cost-0
Net Interest Income11,115
 
Pretax Income (+$)
Operating Income-155,063
Net Interest Income11,115
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-143,948-166,178
EBIT - interestExpense = -155,063
-143,948
-143,948
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-155,063-143,948
Earnings Before Interest and Taxes (EBITDA)-141,409
 
After tax Income (+$)
Income Before Tax-143,948
Tax Provision-0
Net Income From Continuing Ops-143,948-143,948
Net Income-143,948
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses232,050
Total Other Income/Expenses Net11,115-11,115
 

Technical Analysis of Nurix Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nurix Therapeutics Inc. The general trend of Nurix Therapeutics Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nurix Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nurix Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 15.01 < 16.11 < 16.81.

The bearish price targets are: 12.26 > 11.83 > 11.58.

Tweet this
Nurix Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nurix Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nurix Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nurix Therapeutics Inc. The current macd is 0.73061688.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nurix Therapeutics Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Nurix Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Nurix Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Nurix Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartNurix Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nurix Therapeutics Inc. The current adx is 38.32.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Nurix Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Nurix Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nurix Therapeutics Inc. The current sar is 12.31.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Nurix Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nurix Therapeutics Inc. The current rsi is 64.10. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Nurix Therapeutics Inc Daily Relative Strength Index (RSI) ChartNurix Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nurix Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nurix Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Nurix Therapeutics Inc Daily Stochastic Oscillator ChartNurix Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nurix Therapeutics Inc. The current cci is 85.87.

Nurix Therapeutics Inc Daily Commodity Channel Index (CCI) ChartNurix Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nurix Therapeutics Inc. The current cmo is 30.87.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Nurix Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartNurix Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nurix Therapeutics Inc. The current willr is -28.02359882.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Nurix Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Nurix Therapeutics Inc Daily Williams %R ChartNurix Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nurix Therapeutics Inc.

Nurix Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nurix Therapeutics Inc. The current atr is 1.11398919.

Nurix Therapeutics Inc Daily Average True Range (ATR) ChartNurix Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nurix Therapeutics Inc. The current obv is 8,421,790.

Nurix Therapeutics Inc Daily On-Balance Volume (OBV) ChartNurix Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nurix Therapeutics Inc. The current mfi is 33.12.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Nurix Therapeutics Inc Daily Money Flow Index (MFI) ChartNurix Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nurix Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-15ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Nurix Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nurix Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5064.098
Ma 20Greater thanMa 5013.829
Ma 50Greater thanMa 10011.021
Ma 100Greater thanMa 2009.489
OpenGreater thanClose14.540
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nurix Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Nurix Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nurix Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nurix Therapeutics Inc

I send you an email if I find something interesting about Nurix Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Nurix Therapeutics Inc.

Receive notifications about Nurix Therapeutics Inc in your mailbox!